The Sangui Biotech GmbH carries out research and development around the care of the human body with oxygen. Patents and know-how, unique technologies and formulations lead to products and their applications. We place the legalization and marketing of these products in the hands of competent specialists: out-licensing to partners or joint ventures, income from licensing income and dividends. The first major milestone was the market launch of the hemoglobin-based wound spray Granulox by the joint venture SastoMed GmbH. A major project and strategic focus is the development of artificial oxygen carriers (hemoglobin hyperpolymers) as an internal therapy for acute oxygen deficiency.